Christoph Esslinger
Fondateur chez Memo Therapeutics AG
Postes actifs de Christoph Esslinger
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Fondateur | 29/11/2012 | - |
| Directeur Technique/Scientifique/R&D | 29/11/2012 | - | |
| Directeur/Membre du Conseil | 29/11/2012 | - |
Historique de carrière de Christoph Esslinger
Anciens postes connus de Christoph Esslinger
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Neurimmune Therapeutics | Corporate Officer/Principal | - | - |
CT Atlantic Ltd.
 CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Directeur Technique/Scientifique/R&D | 17/09/2009 | - |
| Fondateur | 17/09/2009 | - |
Formation de Christoph Esslinger
| Universität Stuttgart | Graduate Degree |
| University of Lausanne | Doctorate Degree |
Statistiques
Internationale
| Suisse | 5 |
| Allemagne | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Consumer Services | 3 |
| Commercial Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
CT Atlantic Ltd.
CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Commercial Services |
| Neurimmune Therapeutics | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
- Bourse
- Insiders
- Christoph Esslinger
- Expérience
